Professor | Weijia Fang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Weijia Fang
Contact Information	weijiafang@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Weijia Fang

Contact Information

weijiafang@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Medical
Academic Background & Achievements	2008-09 to 2013-06 Medical Doctorate: Zhejiang University School of Medicine 2002-09 to 2005-06 Medical Master's: Zhejiang University School of Medicine 1993-09 to 1998-06 Medical Bachelor's: Zhejiang Medical University 2012 Visiting Scholar: Indiana University, USA 2011 Visiting Scholar: University of Hong Kong
Work Experience	2019-12 to Present - Zhejiang University School of Medicine First Affiliated Hospital - Chief Physician 2008-12 to 2019-12 - Zhejiang University School of Medicine First Affiliated Hospital - Associate Chief Physician 2003-12 to 2008-12 - Zhejiang University School of Medicine First Affiliated Hospital - Attending Physician 1998-09 to 2003-12 - Zhejiang University School of Medicine First Affiliated Hospital - Resident Physician

University/Lab Affiliation and Title

Zhejiang University

Faculty

Medical

Academic Background & Achievements

2008-09 to 2013-06 Medical Doctorate: Zhejiang University School of Medicine
2002-09 to 2005-06 Medical Master's: Zhejiang University School of Medicine
1993-09 to 1998-06 Medical Bachelor's: Zhejiang Medical University
2012 Visiting Scholar: Indiana University, USA
2011 Visiting Scholar: University of Hong Kong

Work Experience

2019-12 to Present - Zhejiang University School of Medicine First Affiliated Hospital - Chief Physician
2008-12 to 2019-12 - Zhejiang University School of Medicine First Affiliated Hospital - Associate Chief Physician
2003-12 to 2008-12 - Zhejiang University School of Medicine First Affiliated Hospital - Attending Physician
1998-09 to 2003-12 - Zhejiang University School of Medicine First Affiliated Hospital - Resident Physician

Areas of Focus	Innovative Cellular Immunotherapy for Solid Tumors
Publications	An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis, Bao X, Wang D, Dai X, Liu C, Zhang H, Jin Y, Tong Z, Li B, Tong C, Xin S, Li X, Wang Y, Liu L, Zhu X, Fu Q, Zheng Y, Deng J, Tian W, Guo T, Zhao P, Chen W, Fang W, 2023 Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy, Jiawei Shi, Junwei Liu, Xiaoxuan Tu, Bin Li, Zhou Tong, Tian Wang, Yi Zheng, Hongyu Shi, Xun Zeng, Wei Chen, Weiwei Yin, Weijia Fang, 2022 Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers, Ruyi Zhang, Marco Puzzoni, Stefano Mariani, Yi Zheng, Nicole Liscia, Yixuan Guo, Clelia Donisi, Yu Liu, Valentino Impera, Weijia Fang, Mario Scartozzi, 2021 Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy, Yizhen Jiang, Xiaoxuan Tu, Xiangying Zhang, Haihong Liao, Shuwen Han, Weiqin Jiang, Yi Zheng, Peng Zhao, Zhou Tong, Qihan Fu, Quan Qi, Junjun Shen, Liping Zhong, Yuefen Pan, Weijia Fang, 2020 Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy, Xuanwen Bao, Hangyu Zhang, Wei Wu, Shaobing Cheng, Xiaomeng Dai, Xudong Zhu, Qihan Fu, Lulu Liu, Yi Zheng, Peng Zhao, Weijia Fang, Fanglong Liu, 2020 Ultra-stable biomembrane force probe for accurately determining slow dissociation kinetics of PD-1 blockade antibodies on single living cells, Chenyi An, Wei Hu, Jie Gao, Bing-Feng Ju, Peyman Obeidy, Yunduo, Charles Zhao, Xiaoxuan Tu, Weijia Fang, Lining Arnold Ju, Wei Chen, 2020 Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligence, Shuiguang Deng, Hailiang Zhao, Weijia Fang, Jianwei Yin, Schahram Dustdar, Albert Y. Zomaya, 2020 Integrated analysis of single‑cell RNA‑seq and bulk RNA‑seq unravels tumour heterogeneity plus M2‑like tumour‑associated macrophage infiltration and aggressiveness in TNBC, Xuanwen Bao, Run Shi, Tianyu Zhao, Yanfang Wang, Natasa Anastasov, Michael Rosemann, Weijia Fang, 2020 Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review, Bin Li, Cong Yan, Jiamin Zhu, Xiaobing Chen, Qihan Fu, Hangyu Zhang, Zhou Tong, Lulu Liu, Yi Zheng, Peng Zhao, Weiqin Jiang, Weijia Fang, 2020 Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab, Hangyu Zhang, Liyun Yuan, Lulu Liu, Cong Yan, Jinming Cheng, Qihan Fu, Zhou Tong, Weiqin Jiang, Yi Zheng, Peng Zhao, Guoqing Zhang, Weijia Fang, 2020 Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma, Yi Zheng, Tingting Wang, Xiaoxuan Tu, Yun Huang, Hangyu Zhang, Di Tan, Weiqin Jiang, Shunfeng Cai, Peng Zhao, Ruixue Song, Peilu Li, Nan Qin, Weijia Fang, 2019 Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients, Zhang H, Liu R, Yan C, Liu L, Tong Z, Jiang W, Yao M, Fang W, Chen Z, 2018 A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin, Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu, Zhou Tong, Hangyu Zhang, Cong Yan, Weijia Fang, Weilin Wang, 2018

Areas of Focus

Innovative Cellular Immunotherapy for Solid Tumors

Publications

An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis, Bao X, Wang D, Dai X, Liu C, Zhang H, Jin Y, Tong Z, Li B, Tong C, Xin S, Li X, Wang Y, Liu L, Zhu X, Fu Q, Zheng Y, Deng J, Tian W, Guo T, Zhao P, Chen W, Fang W, 2023
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy, Jiawei Shi, Junwei Liu, Xiaoxuan Tu, Bin Li, Zhou Tong, Tian Wang, Yi Zheng, Hongyu Shi, Xun Zeng, Wei Chen, Weiwei Yin, Weijia Fang, 2022
Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers, Ruyi Zhang, Marco Puzzoni, Stefano Mariani, Yi Zheng, Nicole Liscia, Yixuan Guo, Clelia Donisi, Yu Liu, Valentino Impera, Weijia Fang, Mario Scartozzi, 2021
Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy, Yizhen Jiang, Xiaoxuan Tu, Xiangying Zhang, Haihong Liao, Shuwen Han, Weiqin Jiang, Yi Zheng, Peng Zhao, Zhou Tong, Qihan Fu, Quan Qi, Junjun Shen, Liping Zhong, Yuefen Pan, Weijia Fang, 2020
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy, Xuanwen Bao, Hangyu Zhang, Wei Wu, Shaobing Cheng, Xiaomeng Dai, Xudong Zhu, Qihan Fu, Lulu Liu, Yi Zheng, Peng Zhao, Weijia Fang, Fanglong Liu, 2020
Ultra-stable biomembrane force probe for accurately determining slow dissociation kinetics of PD-1 blockade antibodies on single living cells, Chenyi An, Wei Hu, Jie Gao, Bing-Feng Ju, Peyman Obeidy, Yunduo, Charles Zhao, Xiaoxuan Tu, Weijia Fang, Lining Arnold Ju, Wei Chen, 2020
Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligence, Shuiguang Deng, Hailiang Zhao, Weijia Fang, Jianwei Yin, Schahram Dustdar, Albert Y. Zomaya, 2020
Integrated analysis of single‑cell RNA‑seq and bulk RNA‑seq unravels tumour heterogeneity plus M2‑like tumour‑associated macrophage infiltration and aggressiveness in TNBC, Xuanwen Bao, Run Shi, Tianyu Zhao, Yanfang Wang, Natasa Anastasov, Michael Rosemann, Weijia Fang, 2020
Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review, Bin Li, Cong Yan, Jiamin Zhu, Xiaobing Chen, Qihan Fu, Hangyu Zhang, Zhou Tong, Lulu Liu, Yi Zheng, Peng Zhao, Weiqin Jiang, Weijia Fang, 2020
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab, Hangyu Zhang, Liyun Yuan, Lulu Liu, Cong Yan, Jinming Cheng, Qihan Fu, Zhou Tong, Weiqin Jiang, Yi Zheng, Peng Zhao, Guoqing Zhang, Weijia Fang, 2020
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma, Yi Zheng, Tingting Wang, Xiaoxuan Tu, Yun Huang, Hangyu Zhang, Di Tan, Weiqin Jiang, Shunfeng Cai, Peng Zhao, Ruixue Song, Peilu Li, Nan Qin, Weijia Fang, 2019
Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients, Zhang H, Liu R, Yan C, Liu L, Tong Z, Jiang W, Yao M, Fang W, Chen Z, 2018
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin, Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu, Zhou Tong, Hangyu Zhang, Cong Yan, Weijia Fang, Weilin Wang, 2018

Cellular Immunotherapy Solid Tumors Clinical Research Car-T Therapy Nk Cells Cancer Treatment Immunotherapy Oncology Clinical Trials Innovative Therapies

Zhaoyou Tang - Fudan University

Xiaojun Xu - Zhejiang University

Hongchuan Jin - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us